GSA Capital Partners’s Opus Genetics IRD Stock Holding History

GSA Capital Partners’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,588	Closed	-$46K	–	2008
2023 Q3	$46K	Buy	+13,588	New	+$54.6K	﹤0.01%	1422

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GSA Capital Partners's IRD Position: Q4 2023 in Review

GSA Capital Partners sold out of Opus Genetics (IRD) in Q4 2023, closing a stake of 13,588 shares — an estimated $46K sold.

GSA Capital Partners first reported a position in IRD in Q3 2023 and held it in 1 quarter. The position peaked at $46K in Q3 2023. 50 funds tracked by Wall St. Rank hold IRD as of Q4 2023.

GSA Capital Partners reported no remaining Opus Genetics position as of Q4 2023 after selling out during the quarter.
GSA Capital Partners sold 13,588 Opus Genetics shares in Q4 2023, an estimated $46K.
GSA Capital Partners first reported a position in Opus Genetics in Q3 2023 and held it in 1 quarter.
GSA Capital Partners's Opus Genetics position peaked at $46K in Q3 2023.
50 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.